Grab Sources And More Key Details Here.
And as I mentioned above, NTRB has 5 key potential catalysts to soak in now. Here they are:
No. 1 NTRB Potential Catalyst - Low Float Volatility Could Take Hold At A Moment's Notice
According to the Yahoo Finance website, NTRB has a low float.
The website reports this profile to have approximately 4.7Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could positive company news early this year help provide a near term spark?
No. 2 NTRB Potential Catalyst - Analyst From Zacks SCR Provides Massive $10 Target
Back in October of 2022, M. Marin, an analyst with Zacks Small-Cap Research, provided NTRB with a $10.00 target.
From Tuesday's closing valuation, that provides NTRB with over 175+% potential upside.
Here's some key highlights from the report:
Given NTRB’s steps to expand its operating footprint and protect its IP, we are optimistic about AVERSA’s commercial prospects, as the potential range of applicable uses for the AVERSA technology, the rising incidences of overdose deaths and high related healthcare costs could translate, we believe, into high demand for AVERSA following clinical studies.
We are encouraged by the estimates from Health Advances. We believe in success NTRB could attain annual revenue in the $10Mn to $15Mn range by 2025-26 on its way to achieving scale and peak sales, depending on the commercialization timeline. We believe these forecasts are supported by the growing size of the target markets and AVERSA’s expected ability to improve the safety profile of fent-a-nyl and other prescription medications. Moreover, we also believe that competitive pressure could lead to adoption of the AVERSA technology by several large pharma companies in a short period, if the technology proves as efficient as NTRB believes it will. In fact, fent-a-nyl transdermal patches have become such an important pain therapy that they have been added to the WHO list of essential medicines, as noted, which we believe supports the positive outlook for AVERSA if clinical test results support its efficacy and safety. If the company can maintain its expected timeline and commercialize AVERSA by late 2024, our forecast could prove conservative, depending on several factors.
It is difficult to compare NTRB to other more mature companies, in our view, given the early stage of development of AVERSA and the product portfolio. We would also expect NTRB to have a higher growth rate in the early years. Various other companies that are engaged in introducing new therapies and solutions and are at a similar stage of development have a wide range of price-to revenue multiples on forward estimates. Nevertheless, we believe the average price-to-sales multiple of companies in this comparison of about 14x provides a valuation benchmark for NTRB. Therefore, applying a 14x multiple to our above-noted forecast revenue range and discounting back to the present at 10%/year results in a present value of about $10 to $15 per share on a fully diluted basis, if the company initiates a successful launch of AVERSA. We expect the shares to begin to reflect the low end of this range as it hits certain milestones and incorporate the mid- to high-end as AVERSA development proceeds. Our forecast could change if and when the company expands the number of products leveraging the AVERSA technology.
While there are several risks to the timeline and commercial launch, we think the current share price does not reflect the fundamental value of the company’s pipeline and prospects and would anticipate multiple expansion as the company continues to advance AVERSA. Any delay or failure in clinical development or regulatory approval could cause the share price to decline and represent a potential risk to our valuation but we believe the risk / reward ratio could be attractive for in-vest-ors who have a higher than average risk tolerance and longer time horizon.
No. 3 NTRB Potential Catalyst - Company Launches Game-Changing "AI Tape" Product Targeting Ever-Growing Consumer Market
Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings
ORLANDO, FL / ACCESSWIRE / July 27, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its consumer sports recovery tape brand, Active Intelligence AI Tape ("AI Tape"), with products now available for purchase on Amazon and Activeintell(dot)com.
AI Tape is designed to combine many of the traditional benefits of kinesiology tape with the addition of soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix.
"We are very excited for the launch of our AI Tape brand, our first products targeting the consumer market," stated Gareth Sheridan, Nutriband CEO. "Consumers looking to take advantage of the sports recovery benefits provided by AI Tape can purchase products, including our Active Intelligence AI Kinesiology Tape, on Amazon or through our Active Intelligence website."
AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina.
Read the full article here.
No. 4 NTRB Potential Catalyst - With A Potential Patent Issuance Nearing, NTRB Looks To Further Protect IP
Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology
ORLANDO, FL / ACCESSWIRE / June 23, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on June 15, 2023 for patent application 17/568,999, "Abuse and Misuse Deterrent Transdermal Systems" which covers its Aversa™ abuse deterrent technology. The receipt of a Notice of Allowance means that the USPTO is expected to issue a U.S. patent for this application after administrative processes have been completed.
The expected issuance of this patent further expands Nutriband's intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary Aversa™ abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband's lead product under development is Aversa™ FEN, an abuse deterrent FEN transdermal system, with the potential to become the first abuse deterrent pain patch on the market.
Read the full article here.
No. 5 NTRB Potential Catalyst - Announcement Of Revenue Up 46% Signals NTRB's Growth Potential
Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023
ORLANDO, FL / ACCESSWIRE / April 27, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced fin-a-ncial and operational results for the fiscal year ended January 31, 2023.
- Generated record revenue of $2.1Mn, up 46% over the prior fiscal year
- Successfully obtained court verdict for recovery of shares constituting 15% of its total outstanding shares
- Announced a Seven-for-Six Forward st-ock split to reward shareholders following the successful court verdict
- Received notice of allowance from the Canadian Intellectual Property Office for AVERSA™ patent completing patent issuance in all of North America
- Demonstrated with Kindeva Drug Delivery enhanced abuse-deterrent characteristics for AVERSA™ FEN
- Company COO, Alan Smith Ph.D selected for FDA Centre for Research on Complex Generics Expert Committee
- With Kindeva Drug Delivery, selected AVERSA™ FEN Abuse Deterrent Formulation for commercial scale manufacturing process development
"Our 2022 results and milestones have shown that we remain laser focused on hitting the targets we set ourselves as a company each year. We have made significant progress with AVERSA™ and our goal to improve the safety profile of easily abused transdermal drugs. Our record fin-an-cial results and multiple major achievements in fiscal 2022 were a direct result of the hard work and exceptional execution of our dedicated team," commented Gareth Sheridan, CEO of Nutriband. "We look forward to continuing to positively update our shareholders as we have laid out major milestone targets for 2023 which we intend to achieve as in previous years.''
"According to an assessment by Health Advances, AVERSA™ FEN could reach peak annual sales of between $80Mn and $200Mn. If the entire transdermal FEN market moves toward abuse deterrent patches, similar to what occurred in the extended-release oral opioid market, the potential could be significantly greater," continued Sheridan. "I want to thank our shareholders for their ongoing support as we continue to execute on our vision of commercializing our innovative transdermal abuse deterrent technology, AVERSA™."
Read the full article here.
NTRB Recap - 5 Key Potential Breakout Catalysts For This Nasdaq Idea
No. 1 - Low Float Volatility Could Take Hold At A Moment's Notice
No. 2 - Analyst From Zacks SCR Provides Massive $10 Target
No. 3 - Company Launches Game-Changing "AI Tape" Product Targeting Ever-Growing Consumer Market
No. 4 - With A Potential Patent Issuance Nearing, NTRB Looks To Further Protect IP
No. 5 - Announcement Of Revenue Up 46% Signals NTRB's Growth Potential
Coverage is officially reinitiated on NTRB. When time allows it, do this: